OA06-LBA01.4. A Multimodal Classifier to Stratify Response to Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on RCT-HCHTOG1909

Clicks: 20
ID: 326089
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #204 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background The predictive utility of the PD-L1 combined positive score (CPS) for neoadjuvant immuno-chemotherapy in locally advanced esophageal squamous cell carcinoma (ESCC) remains suboptimal, highlighting a critical unmet need for better patient stratification. Methods we performed bulk RNA sequencing (RNA-seq), whole-exome sequencing (WES), and shallow whole-genome sequencing (sWGS) on pretreatment tumor samples from 102 patients enrolled in the HCHTOG1909 trial. Additionally, for a subset of these patients (N=80) for whom matched posttreatment samples available, we conducted a paired longitudinal analysis to investigate therapy-induced molecular changes. Through this approach, we identified baseline predictive biomarkers, including a gene expression signature and genomic alterations (CNVs/SNVs), and investigated therapy-induced dynamic changes associated with treatment response. Results By integrating these molecular features with macroscopic type and PD-L1 status, we developed the esophageal cancer multimodal immuno-chemotherapy classifier (EMIC), which effectively stratifies patients into two groups with distinct therapeutic responses: EMIC1 (predicted to benefit from combined immuno-chemotherapy) and EMIC2 (predicted to have equivalent outcomes with chemotherapy alone), providing a rationale for personalized treatment de-escalation. Conclusion In conclusion, by integrating bulk RNA-seq, whole-exome sequencing, and shallow whole-genome sequencing data from pretreatment tumor samples of 102 patients in the HCHTOG1909 trial, we have identified robust baseline predictive biomarkers. This multi-omics framework enables precise stratification of neoadjuvant chemotherapy patients who do not require addition of PD-1 antibody(EMIC2), allowing them to avoid the burden of ineffective treatment and immune-related adverse events. Future external validation and prospective clinical assessment will be essential to translate these integrative biomarkers into routine practice for personalized treatment decision-making.
Reference Key
openalex_W7203994541 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yan Zheng, Wenqun Xing, MD Ji Wang, Guanghui Liang
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.045
URL
https://doi.org/10.1093/dote/doag077.045
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.